Melanie Mason, RN | |
3074 W Lake Mary Blvd Ste 132, Lake Mary, FL 32746-6749 | |
(407) 917-0322 | |
Not Available |
Full Name | Melanie Mason |
---|---|
Gender | Female |
Speciality | Marriage & Family Therapist |
Location | 3074 W Lake Mary Blvd Ste 132, Lake Mary, Florida |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1427585751 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
163W00000X | Registered Nurse | 9305106 (Florida) | Secondary |
106H00000X | Marriage & Family Therapist | MT3456 (Florida) | Primary |
Mailing Address | Practice Location Address |
---|---|
Melanie Mason, RN 3715 N Business Dr Ste 202, Fayetteville, AR 72703-5288 Ph: () - | Melanie Mason, RN 3074 W Lake Mary Blvd Ste 132, Lake Mary, FL 32746-6749 Ph: (407) 917-0322 |
News Archive
By combining two treatment strategies, both aimed at boosting the immune system's killer T cells, Johns Hopkins researchers report they lengthened the lives of mice with skin cancer more than by using either strategy on its own.
Healthy individuals with higher levels of albumin excretion, even levels considered normal, are at increased risk of developing hypertension (high blood pressure), according to a study appearing in the October 2008 issue of the Journal of the American Society Nephrology (JASN).
The first study to measure the full spectrum of age-related damage to all five senses found that 94 percent of older adults in the United States have at least one sensory deficit, 38 percent have two, and 28 percent have three, four or five.
For a promising pathway to treating Alzheimer's patients, "aim here." That's what National Institute of Standards of Technology researchers advised collaborators hunting for molecules that, by linking to a normally occurring enzyme, rev up the brain's capacity for clearing cholesterol-a boost associated with improvements in memory and other benefits in animal studies.
Medinol, a developer of Interventional Cardiology devices, announced today the completion of enrollment in its BIONICS trial, a global, prospective, randomized, multicenter, clinical trial designed to evaluate the safety and effectiveness of a new Coronary Stent System, the first ever elastomeric Drug Eluting Stent or eDES.
› Verified 3 days ago